Antimicrobial Resistance – Navigating obstacles in R&D and commercialization
The lack of innovation surrounding the development of new antibiotics has resulted in an alarming situation, given the rising threat of antimicrobial resistance (AMR).
As a result, there is no single or straightforward way to combat AMR, nor to galvanize development of novel antibiotics. Although some positive measures have been introduced, further – and larger scale – action is needed.
Since the initial era of discovery in the mid-20th century, there has been a lackluster level of innovation in the antibiotics field, and today there are few novel antibiotic classes in development despite the urgency of medical need.
The lagging antimicrobial innovation has certainly made its impact felt. Estimates suggest that resistant infections underlie nearly 700,000 global deaths each year – a figure projected by some to rise to 10 million each year by 2050.
New resistance mechanisms are emerging and spreading globally, threatening our ability to treat common infectious diseases, resulting in prolonged illness, disability, and death. Each year in the US alone, the CDC reports that at least 2 million people contract an antibiotic-resistant infection, with an estimated annual attributable death toll of 23,000.
You may also be interested in…
China Pharma Market Access (CPMA)
Since the establishment of the China National Medical Insurance Bureau in 2018, the goal has been to strengthen public health and medical service levels, achieve maximum utilisation of the national medical insurance fund, and to enhance the strategic purchasing capability of medical insurance funds. Significant tools in achieving this are the National Reimbursement Drug List (NRDL) and drug Volume Based Procurement (VBP), which have opened a new chapter in China’s medical reform. Meanwhile, the new drug registration process is improved, simplified, and accelerated.
George Gu attends DIA meeting in Suzhou
George Gu, Principal and Head of China at Deallus, recently attended the 2023 DIA China Annual Conference where he participated in an expert panel discussion on "Post-Marketing Medical Activities Based on Specialty Drug Pharmacy Management Platform".
Maximise product value through Medical Insights
Medical Insights is emerging as a transformative organisational capability within Medical Affairs that aims to capture real-world insights through medical channels and use them to maximise product and portfolio value.